<DOC>
	<DOCNO>NCT00307528</DOCNO>
	<brief_summary>As license Pneumovax 23™ vaccine always satisfactory elderly subject , safety immune response new investigational pneumococcal protein vaccine evaluate healthy elderly population .</brief_summary>
	<brief_title>Safety Efficacy Study Investigational Pneumococcal Vaccine Elderly Population</brief_title>
	<detailed_description>Since influenza vaccination recommend age range study population , Fluarix™ ( GlaxoSmithKline Biologicals ) vaccine offer free charge study period ( 3 consecutive year start September 2004 ) , use Investigators accord national vaccination schedule/practice . The Protocol Posting update order comply FDA Amendment Act , Sep 2007 .</detailed_description>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Pneumococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Inclusion criterion Subjects investigator believe comply requirement protocol A male female ≥ 65 year time first vaccination . Written inform consent obtain subject . Free obvious health problem establish medical history clinical examination enter study . Exclusion criterion Use investigational nonregistered product ( drug vaccine ) study vaccine ( ) within 30 day precede first dose study vaccine , plan use study period participation another pharmaceutical/vaccine study . Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug within six month prior first vaccine dose . Use anticoagulant . Planned administration/ administration vaccine foreseen study protocol within 2 week first dose vaccine . Previous vaccination Streptococcus pneumoniae . Bacterial pneumonia within 3 year prior 1st vaccination . Any confirm suspected immunosuppressive immunodeficient condition , include human immunodeficiency virus ( HIV ) infection . History allergic disease reaction likely exacerbate component vaccine . Current serious neurologic mental disorder . Currently smoke &gt; 25 cigarette per day . Inflammatory process know chronic active infection All malignancy ( exclude nonmelanic skin cancer ) lymphoproliferative disorder diagnose treat actively past 5 year . History administration experimental vaccine contain MPL QS21 . Acute disease time enrolment . Acute chronic , clinically significant pulmonary , cardiovascular , hepatic renal functional abnormality , determine physical examination laboratory screening test , discretion investigator . History chronic alcohol consumption and/or intravenous drug abuse .</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
</DOC>